Lenvima

Active Ingredient(s): Lenvatinib
FDA Approved: * February 13, 2015
Pharm Company: * EISAI INC
Category: Cancer

Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.[1] Contents 1 Medical uses 2 Adverse effects 3 Interactions 4 Pharmacology 4.1 Mechanism of action 4.2 Pharmacokinetics 5 Chemistry 6 History 7 Brand names 8 References 9 External links ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lenvima 4 mg Oral Capsule
NDC: 62856-704
Labeler:
Eisai Inc.
Lenvima 4 mg Oral Capsule
NDC: 62856-708
Labeler:
Eisai Inc.
Lenvima 10 mg Oral Capsule
NDC: 62856-710
Labeler:
Eisai Inc.
Lenvima 4 mg Oral Capsule
NDC: 62856-712
Labeler:
Eisai Inc.
Lenvima Kit
NDC: 62856-714
Labeler:
Eisai Inc.
Lenvima Kit
NDC: 62856-718
Labeler:
Eisai Inc.
Lenvima 10 mg Oral Capsule
NDC: 62856-720
Labeler:
Eisai Inc.
Lenvima Kit
NDC: 62856-724
Labeler:
Eisai Inc.